Glioblastoma

Scientists find how cancers can evade treatment

The drugs were designed to keep cancer cells at bay by preventing their growth, survival and spread. Yet, after clinical trials, they left scientists scratching their heads and drug developers watching their ...

Jan 15, 2015
popularity 4.6 / 5 (12) | comments 1

Revamped drug may overcome resistance in brain tumours

Cancer Research UK scientists have taken steps to overcome drug resistance in glioblastoma, the most common type of brain tumour in adults, according to research published in Molecular Cancer Therapeutics.

Jan 14, 2015
popularity not rated yet | comments 0

New target identified for potential brain cancer therapies

Researchers from Virginia Commonwealth University (VCU) Massey Cancer Center and the VCU Institute for Molecular Medicine (VIMM) have identified a new protein-protein interaction that could serve as a target for future therapies ...

Jan 13, 2015
popularity 5 / 5 (1) | comments 0

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Brazil finds coffee protein with morphine effect

Brazilian scientists have discovered a protein in coffee that has effects similar to pain reliever morphine, researchers at the state University of Brasilia (UnB) and state-owned Brazilian Agricultural Research ...